When to use in situ hybridization for the detection of Epstein-Barr virus: a review of Epstein-Barr virus-associated lymphomas

被引:0
|
作者
Shin-ichi Nakatsuka
Keiichirou Homma
Katsuyuki Aozasa
机构
[1] Kansai Rosai Hospital,Department of Pathology
[2] Osaka University Graduate School of Medicine,Department of Pathology
[3] Osaka University,undefined
来源
关键词
Malignant lymphoma; Epstein-Barr virus; In situ hybridization; Immunodeficiency;
D O I
暂无
中图分类号
学科分类号
摘要
Epstein-Barr (EBV) is the first virus supposed to be causative for human neoplasm. To date, list of EBV-associated lymphomas includes Burkitt lymphoma, Hodgkin lymphoma, pyothorax-associated lymphoma, primary effusion lymphoma, nasal type extranodal natural killer/T cell lymphoma, plasmablastic lymphoma, immunodeficiency-associated lymphoproliferative disorders, and lymphomatoid granulomatosis. In these diseases, presence of EBV could be detected at protein level by immunohistochemistry and at genetical level by polymerase chain reaction and in situ hybridization both applicable on routinely processed formalin-fixed, paraffin-embedded specimens. Clonality of EBV-infected cells could be examined by Southern blot analysis. EBV status examined using these ancillary diagnostic tools were informative for diagnosis of lymphoma, especially diseases developing under immunodeficient condition and diseases showing polymorphous histology with or without large multinucleated cell like a Hodgkin–Reed Sternberg cell. Comprehensive evaluation of clinical presentation, histology, immunohistochemistry, genetic aberration, and EBV status enable accurate diagnosis of EBV-associated lymphoma.
引用
收藏
页码:61 / 70
页数:9
相关论文
共 50 条
  • [1] When to use in situ hybridization for the detection of Epstein-Barr virus: a review of Epstein-Barr virus-associated lymphomas
    Nakatsuka, Shin-ichi
    Homma, Keiichirou
    Aozasa, Katsuyuki
    [J]. JOURNAL OF HEMATOPATHOLOGY, 2015, 8 (02) : 61 - 70
  • [2] Epstein-Barr Virus-Associated Lymphomas
    Grywalska, Ewelina
    Rolinski, Jacek
    [J]. SEMINARS IN ONCOLOGY, 2015, 42 (02) : 291 - 303
  • [3] Epstein-Barr virus-associated lymphomas
    Rickinson, AB
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 29 - 29
  • [4] Epstein-Barr virus-associated lymphomas
    Shannon-Lowe, Claire
    Rickinson, Alan B.
    Bell, Andrew I.
    [J]. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2017, 372 (1732)
  • [5] IMMUNOBIOLOGY OF EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOMAS
    ROCHFORD, R
    MOSIER, DE
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 71 (03): : 256 - 259
  • [6] Epstein-Barr virus-associated lymphoproliferations and lymphomas
    Anagnostopoulos, I.
    Joehrens, K.
    [J]. PATHOLOGE, 2013, 34 (03): : 262 - 271
  • [7] Epstein-Barr virus-associated lymphomas decoded
    Bednarska, Karolina
    Chowdhury, Rakin
    Tobin, Joshua W. D.
    Swain, Fiona
    Keane, Colm
    Boyle, Stephen
    Khanna, Rajiv
    Gandhi, Maher K.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (02) : 415 - 433
  • [8] Targeting Epstein-Barr Virus-Associated Lymphomas
    Nikiforow, Sarah
    LaCasce, Ann S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) : 830 - 832
  • [9] Epstein-Barr virus vectors for the treatment of Epstein-Barr virus-associated cancers
    Paillard, F
    [J]. HUMAN GENE THERAPY, 1998, 9 (08) : 1119 - 1120
  • [10] Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
    Pei, Yonggang
    Wong, Josiah H. Y.
    Robertson, Erle S.
    [J]. CANCERS, 2020, 12 (09) : 1 - 21